KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Liabilities: 2018-2024

Historic Total Liabilities for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $732.5 million.

  • Esperion Therapeutics' Total Liabilities rose 19.15% to $815.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $815.4 million, marking a year-over-year increase of 19.15%. This contributed to the annual value of $732.5 million for FY2024, which is 10.86% up from last year.
  • Per Esperion Therapeutics' latest filing, its Total Liabilities stood at $732.5 million for FY2024, which was up 10.86% from $660.8 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Total Liabilities ranged from a high of $732.5 million in FY2024 and a low of $449.4 million during FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $660.8 million (2023), whereas its average is $655.0 million.
  • Per our database at Business Quant, Esperion Therapeutics' Total Liabilities spiked by 131.05% in 2020 and then dropped by 1.18% in 2022.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Total Liabilities stood at $449.4 million in 2020, then rose by 28.74% to $578.5 million in 2021, then fell by 1.18% to $571.7 million in 2022, then increased by 15.58% to $660.8 million in 2023, then grew by 10.86% to $732.5 million in 2024.